Reader guide · 15 released stories

Evidence at a glance

Start with the outcome a study actually measured. Then keep the population, design, bottom line, and boundary together.

Reading key

Keep four questions together.

Question
What intervention or exposure was examined?
Context
Who or what was studied, and how?
Outcome
What did the released evidence report?
Boundary
What does the story explicitly not establish?

Outcome group

Function & independence

What changed in mobility, sleep, strength, bone density, or day-to-day function?

Story and questionPopulation and designReleased bottom lineBoundary

exercise · physical function · healthy aging

Exercise has strong evidence for function—not proof of slower biological aging

Human function · mature randomized evidence

Human function

mature randomized evidence

Human trials support mobility and physical function in defined populations. Lifespan and biological-age claims require separate evidence.

Exercise has strong evidence for function—not proof of slower biological aging

Story metadata verified

LIFTMOR · resistance training · bone density

LIFTMOR improved bone density in a small supervised trial—not fracture prevention

Human BMD and function · small supervised randomized trial

Human BMD and function

small supervised randomized trial

LIFTMOR found BMD and function gains in a small, screened, closely supervised trial—not fracture prevention or proof that unsupervised heavy training is safe.

LIFTMOR improved bone density in a small supervised trial—not fracture prevention

Story metadata verified

CBT-I · insomnia · older adults

CBT-I improves later-life insomnia—not aging itself

Human sleep outcomes · randomized behavioral trials

Human sleep outcomes

randomized behavioral trials

Two randomized trials support meaningful sleep improvement in older adults; they did not test dementia prevention, biological aging or lifespan.

CBT-I improves later-life insomnia—not aging itself

Story metadata verified

Outcome group

Disease & clinical events

What changed in cardiovascular events, fractures, or other clinical outcomes?

Story and questionPopulation and designReleased bottom lineBoundary

CPAP · obstructive sleep apnea · cardiovascular outcomes

CPAP improved symptoms—not cardiovascular events in major trials

Human cardiovascular and symptom outcomes · large randomized trials

Human cardiovascular and symptom outcomes

large randomized trials

SAVE and ISAACC did not significantly reduce their primary cardiovascular outcomes; SAVE separately found symptom and quality-of-life benefits.

CPAP improved symptoms—not cardiovascular events in major trials

Story metadata verified

blood pressure · cardiovascular disease · cognitive aging

SPRINT reduced cardiovascular events—not aging itself

Human clinical outcomes · large randomized trial

Human clinical outcomes

large randomized trial

Intensive treatment lowered cardiovascular events and mortality in eligible high-risk adults, with more hypotension, electrolyte problems and kidney injury.

SPRINT reduced cardiovascular events—not aging itself

Story metadata verified

zoledronic acid · osteoporosis · fractures

Zoledronic acid reduced fractures in osteoporosis—not aging itself

Human fracture outcomes · large randomized trial

Human fracture outcomes

large randomized trial

HORIZON reduced vertebral and hip fractures in postmenopausal osteoporosis, with outcome-specific duration and safety limits—not evidence of slower aging.

Zoledronic acid reduced fractures in osteoporosis—not aging itself

Story metadata verified

Outcome group

Cognition & dementia

What changed on cognitive tests, trained abilities, or dementia-related outcomes?

Story and questionPopulation and designReleased bottom lineBoundary

FINGER · cognitive aging · multidomain intervention

FINGER slightly improved cognitive-test scores. It did not prove dementia prevention

Human cognitive tests · randomized multidomain trial

Human cognitive tests

randomized multidomain trial

A combined two-year program produced a small cognitive-test advantage; it cannot identify a winning component or establish dementia, disability, mortality, healthspan, or lifespan benefit.

FINGER slightly improved cognitive-test scores. It did not prove dementia prevention

Story metadata verified

MIND diet · cognitive aging · dietary patterns

The MIND diet trial found no cognitive edge over its active control

Human cognition and MRI · randomized dietary trial

Human cognition and MRI

randomized dietary trial

Both groups improved with counseling and calorie restriction; the between-group cognitive difference was not significant and MRI measures were similar.

The MIND diet trial found no cognitive edge over its active control

Story metadata verified

cognitive training · ACTIVE · dementia evidence

Cognitive training improved practiced skills—not survival or proven dementia prevention

Human trained abilities and long-term outcomes · randomized trial plus disputed secondary analysis

Human trained abilities and long-term outcomes

randomized trial plus disputed secondary analysis

ACTIVE supports trained-ability gains and some function signals, found no mortality benefit, and leaves a claims-based dementia subgroup methodologically disputed.

Cognitive training improved practiced skills—not survival or proven dementia prevention

Story metadata verified

Outcome group

Biomarkers & measurements

What changed in a measurement, and what did that measurement not prove?

Story and questionPopulation and designReleased bottom lineBoundary

epigenetic clocks · DNA methylation · biomarkers

What an epigenetic clock can—and cannot—tell you

Biomarker methods · human validation evidence

Biomarker methods

human validation evidence

Different clocks target different constructs. A score is not a diagnosis, and changing it does not prove longer life.

What an epigenetic clock can—and cannot—tell you

Story metadata verified

NAD biology · supplements · biomarkers

NAD precursors raise some metabolites; human longevity benefits remain unproven

Human biomarkers · small trials

Human biomarkers

small trials

Small trials show target engagement, not broad clinical, healthspan or lifespan benefit—and products and routes are not interchangeable.

NAD precursors raise some metabolites; human longevity benefits remain unproven

Story metadata verified

multivitamins · cognitive aging · epigenetic clocks

Multivitamins moved some tests and aging clocks. What does that mean?

Human cognitive tests and biomarkers · correlated randomized substudies

Human cognitive tests and biomarkers

correlated randomized substudies

COSMOS found small cognitive-test differences and modest movement in two DNA-methylation clocks; neither establishes dementia prevention or longer life.

Multivitamins moved some tests and aging clocks. What does that mean?

Story metadata verified

Outcome group

Mortality, healthspan & lifespan

Was survival or longer healthy life actually measured?

Story and questionPopulation and designReleased bottom lineBoundary

partial reprogramming · gene therapy · optic nerve

Partial-reprogramming trial is testing eye-treatment safety—not human rejuvenation

Early human safety trial · no results yet

Early human safety trial

no results yet

A recruiting Phase 1 eye study asks whether ER-100 can be administered safely. It has no posted human efficacy results and does not test lifespan.

Partial-reprogramming trial is testing eye-treatment safety—not human rejuvenation

Story metadata verified

rapamycin · mTOR · clinical trials

PEARL trial found no change in its main visceral-fat outcome

Human outcomes · small randomized trial

Human outcomes

small randomized trial

The 48-week randomized trial reported a null primary outcome, exploratory signals and substantial limits on broader healthy-aging claims.

PEARL trial found no change in its main visceral-fat outcome

Story metadata verified

calorie restriction · metabolism · biomarkers

CALERIE tested calorie restriction for two years—not human lifespan

Human outcomes and biomarkers · randomized trial

Human outcomes and biomarkers

randomized trial

A randomized trial found selected cardiometabolic improvements, while aging-biomarker results were mixed and lifespan was not measured.

CALERIE tested calorie restriction for two years—not human lifespan

Story metadata verified

Method

Built from released coverage, not a new evidence review.

Every row mirrors the canonical title, summary, evidence scope, topic labels, route, and verification date of an already-published story. Open the story for sources, populations, endpoints, limitations, conflicts, funding, and safety context.

Read the editorial standards